The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Open accessAbstract
Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a complex consisting of YAP, TAZ, TEADs, and AP-1 (dimer of cFos and transcription factor Jun [JUN] families) was found to synergistically regulate the transcription of target genes (35–37).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have demonstrated that activated Yap, through genetic amplification of YAP- or WNT5a-mediated dysregulation of the Hippo pathway, enables bypass of Kras suppression in Kras-driven murine pancreatic cancer and lung cancer models (37–39).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“YAP, a pivotal EMT regulator gene, can restore oncogenicity in murine tumors that have lost KRAS [54,131].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies using inducible suppression of KRAS via RNA interference or genetically engineered inducible KrasG12D alleles (i.e., “iKras” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRASG12D suppression (35–38).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using a genetically engineered mouse (GEM) model of PDAC driven by inducible KRASG12D, we recently demonstrated that activation of the YAP1 oncogene drives resistance to genetic inactivation of KRAS∗, a finding further confirmed in KRAS∗-driven colorectal cancer (CRC).”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The YAP1 oncogene has been well established as one of the major drivers of bypassing oncogene addiction and promoting acquired resistance to targeted therapies in several cancer types, including pancreatic cancer, lung cancer, colorectal cancer, melanoma, and glioblastoma.9,10,38,39,40”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“In the context of pancreatic cancer, KRAS dependency can be by-passed by the elevated expression of the transcription factor YAP1, which promotes EMT and confers cell-intrinsic resistance to KRAS loss (84, 85).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [84]
In the citing paper
“On the one hand, it is known that YAP activity is positively correlated with the resistance to therapies targeting KRAS signaling components including RAF and MEK,[ 28, 46 ] and YAP is required for KRAS‐dependent cell transformation: extracellular supplementation of YAP activators can rescue cancer cell killing after KRAS knockdown.[ 47 ]”
From Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Self-citationTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,423
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citation
Flagged first, then by citations
1 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
EMT Transition States during Tumor Progression and Metastasis
Pastushenko, I., & Blanpain, C. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.001 · Cited by 2,866
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,873
Integrated genomic and molecular characterization of cervical cancer
Burk, R. D., Chen, Z., Cf, S., Tarvin, K., Carvalho, A. L., Scapulatempo‐Neto, C., Silveira, H. C. S., Fregnani, J. H. T. G., Creighton, C. J., Anderson, M. L., et al. (2017) · Nature · doi:10.1038/nature21386 · Cited by 1,604
Self-citationGenome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., & Piccolo, S. (2015) · Nature Cell Biology · doi:10.1038/ncb3216 · Cited by 1,219
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3876 · Cited by 1,181
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Chen, S., Sanjana, N. E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D. A., Song, J., Pan, J. Q., Weissleder, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.038 · Cited by 862
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
The Hippo Signaling Pathway in Development and Disease
Zheng, Y., & Pan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.003 · Cited by 867
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 800
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
YAP regulates cell mechanics by controlling focal adhesion assembly
Nardone, G., Cruz, J. O. L., Vrbský, J., Martini, C., Přibyl, J., Skládal, P., Pešl, M., Caluori, G., Pagliari, S., Martino, F. D., et al. (2017) · Nature Communications · doi:10.1038/ncomms15321 · Cited by 682
Laklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G., Barrett, A., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 614
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lü, X., Dey, P., Deng, P., Wu, C.-C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 566
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.001 · Cited by 500
Self-citationKurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 467
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 433
Adhesion to fibronectin regulates Hippo signaling via the FAK–Src–PI3K pathway
Kim, N., & Gumbiner, B. M. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201501025 · Cited by 441
YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers
Stein, C., Bardet, A. F., Roma, G., Bergling, S., Clay, I., Ruchti, A., Agarinis, C., Schmelzle, T., Bouwmeester, T., Schübeler, D., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005465 · Cited by 414
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
YAP and TAZ: a signalling hub of the tumour microenvironment
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0168-y · Cited by 384
YAP/TAZ functions and their regulation at a glance
Pocaterra, A., Romani, P., & Dupont, S. (2020) · Journal of Cell Science · doi:10.1242/jcs.230425 · Cited by 389
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360
McCormick, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2662 · Cited by 320
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 355
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T. K., Leithe, E., & Lothe, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 336
Genetics, diagnosis and management of colorectal cancer (Review)
Rosa, M. D., Pace, U., Rega, D., Costabile, V., Duraturo, F., Izzo, P., & Delrio, P. (2015) · Oncology Reports · doi:10.3892/or.2015.4108 · Cited by 326
Mutational dynamics between primary and relapse neuroblastomas
Schramm, A. R., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beißer, D., Ernst, C., Henssen, A. G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3349 · Cited by 305
LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells
Zhu, P., Wang, Y., Wu, J., Huang, G., Liu, B., Ye, B., Du, Y., Gao, G., Tian, Y., He, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms13608 · Cited by 297
Establishment of mouse expanded potential stem cells
Yang, J. P., Ryan, D. J., Wang, W., Tsang, J. C.-H., Lan, G., Masaki, H., Gao, X., Antunes, L., Yu, Y., Zhu, Z., et al. (2017) · Nature · doi:10.1038/nature24052 · Cited by 301
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance
Weiß, F., Lauffenburger, D. A., & Friedl, P. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-021-00427-0 · Cited by 295
Shih, D. J. H., Nayyar, N., Bihun, I. V., Dagogo‐Jack, I., Gill, C. M., Aquilanti, E., Bertalan, M. S., Kaplan, A. B., D’Andrea, M. R., Chukwueke, U. N., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0592-7 · Cited by 296
Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ
Kim, M., Kim, T., Johnson, R. L., & Lim, D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.015 · Cited by 293
YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Noguchi, S. F., Saito, A., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113674 · Cited by 295
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“…of KRAS via RNA interference or genetically engineered inducible Kras G12D alleles (i.e., “ iKras ” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRAS G12D suppression (35–38).”
BackgroundPlatelets reduce anoikis and promote metastasis by activating YAP1 signaling
Haemmerle, M., Taylor, M., Gutschner, T., Pradeep, S., Cho, M. S., Sheng, J., Lyons, Y., Nagaraja, A. S., Dood, R. L., Wen, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00411-z · Cited by 274
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 282
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 277
Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chénard, M., Long, B. J., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 266
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
Kim, M. H., Kim, J., Hong, H., Lee, J. J.-K., Lee, J., Jung, E., & Kim, J. (2015) · The EMBO Journal · doi:10.15252/embj.201592081 · Cited by 270
Self-citationYAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy
Thompson, B. J. (2020) · BioEssays · doi:10.1002/bies.201900162 · Cited by 262
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis
Qiao, Y., Chen, J., Lim, Y. B., Finch‐Edmondson, M., Seshachalam, V. P., Qin, L., Jiang, T., Low, B. C., Singh, H. P., Lim, C. T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.075 · Cited by 257
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells
Basu-Roy, U., Bayin, N. S., Rattanakorn, K., Han, E. J., Placantonakis, D. G., Mansukhani, A., & Basilico, C. (2015) · Nature Communications · doi:10.1038/ncomms7411 · Cited by 257
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
The Hippo Pathway in Liver Homeostasis and Pathophysiology
Driskill, J. H., & Pan, D. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-030420-105050 · Cited by 234
YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity
Ni, X., Tao, J., Barbi, J. J., Chen, Q., Park, B. V., Li, Z., Zhang, N., Lebid, A., Ramaswamy, A., Wei, P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1124 · Cited by 240
Tead and AP1 Coordinate Transcription and Motility
Liu, X., Li, H., Rajurkar, M., Li, Q., Cotton, J. L., Ou, J., Zhu, L. J., Goel, H. L., Mercurio, A. M., Park, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.104 · Cited by 241
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Chen, H.-A., Ho, Y.-J., Mezzadra, R., Adrover, J. M., Smolkin, R. M., Zhu, C., Woess, K., Bernstein, N., Schmitt, G., Fong, L. E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0528 · Cited by 241
Wei, S. C., & Yang, J. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.09.009 · Cited by 230
Panciera, T., Citron, A., Biagio, D. D., Battilana, G., Gandin, A., Giulitti, S., Forcato, M., Bicciato, S., Panzetta, V., Fusco, S., et al. (2020) · Nature Materials · doi:10.1038/s41563-020-0615-x · Cited by 236
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2016) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 218
Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215
Chen, J., Sun, Y., Xu, X., Wang, D., He, J., Zhou, H., Lu, Y., Zeng, J., Du, F., Gong, A., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1380125 · Cited by 211
Sun, Z., Ou, C., Liu, J., Chen, C., Zhou, Q., Yang, S., Li, G., Wang, G., Song, J., Li, Z., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0628-y · Cited by 209
RetractedTankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins
Wang, W., Li, N., Li, X., Tran, M. K., Han, X., & Chen, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.014 · Cited by 209
Hsu, P., Jablons, D. M., Yang, C., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 215
Sarcomatoid renal cell carcinoma: biology, natural history and management
Blum, K. A., Gupta, S., Tickoo, S. K., Chan, T. A.-T., Russo, P., Motzer, R. J., Karam, J. A., & Hakimi, A. A. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00382-9 · Cited by 211
Cell plasticity in epithelial homeostasis and tumorigenesis
Varga, J., & Greten, F. R. (2017) · Nature Cell Biology · doi:10.1038/ncb3611 · Cited by 209
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature · doi:10.1038/nature19771 · Cited by 202
Self-citationZhang, W. C., Chin, T. M., Yang, H. H., Nga, M. E., Lunny, D. P., Lim, E. K. H., Sun, L., Pang, Y. H., Leow, Y. N., Malusay, S. R. Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11702 · Cited by 202
Song, S., Xie, M., Scott, A. W., Jin, J., Ma, L., Dong, X., Skinner, H. D., Johnson, R. L., Ding, S., & Ajani, J. A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0560 · Cited by 205
The Role of Hippo Pathway in Cancer Stem Cell Biology.
Park, J. H., Shin, J. E., & Park, H. W. (2018) · PubMed Central · doi:10.14348/molcells.2018.2242 · Cited by 197
KRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 189
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Self-citationKRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J. M., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 192
A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy
Shibata, M., Ham, K., & Hoque, M. O. (2018) · International Journal of Cancer · doi:10.1002/ijc.31561 · Cited by 190
Breast cancer stem cells: Features, key drivers and treatment options
Dittmer, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.007 · Cited by 190
Xu, W., Zhou, G., Wang, H., Liu, Y., Chen, B., Chen, W., Chen, L., Wu, S., Gong, A., & Xu, M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32747 · Cited by 186
Ashrafizadeh, M., Mirzaei, S., Hashemi, F., Zarrabi, A., Zabolian, A., Saleki, H., Sharifzadeh, S. O., Soleymani, L., Daneshi, S., Hushmandi, K., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111824 · Cited by 187
RetractedCRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
Mou, H., Smith, J. L., Peng, L., Yin, H., Moore, J. E., Zhang, X.-O., Song, C., Sheel, A., Wu, Q., Özata, D. M., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1237-8 · Cited by 190
Self-citationGlucocorticoid receptor signalling activates YAP in breast cancer
Sorrentino, G., Ruggeri, N., Zannini, A., Ingallina, E., Bertolio, R., Marotta, C., Neri, C., Cappuzzello, E., Forcato, M., Rosato, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms14073 · Cited by 179
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer
Yimlamai, D., Fowl, B. H., & Camargo, F. D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.008 · Cited by 177
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis
Lamar, J. M., Xiao, Y., Norton, E., Jiang, Z.-G., Gerhard, G. M., Kooner, S., Warren, J. S. A., & Hynes, R. O. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004364 · Cited by 169
Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways
Santinon, G., Pocaterra, A., & Dupont, S. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.11.004 · Cited by 169
The Hippo pathway in normal development and cancer
Maugeri‐Saccà, M., & Maria, R. D. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.011 · Cited by 169
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 167
Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M. P., Haider, S. M., Morton, J. P., Marsico, G., Vo, T. D., Laughlin, S., Ahmed, A. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01781 · Cited by 168
Control of stem cell renewal and fate by YAP and TAZ
Driskill, J. H., & Pan, D. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00644-5 · Cited by 173
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Bora-Singhal, N., Nguyen, J. V., Schaal, C. M., Perumal, D., Singh, S., Coppola, D., & Chellappan, S. (2015) · Stem Cells · doi:10.1002/stem.1993 · Cited by 162
miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis
Kang, W., Huang, T., Zhou, Y., Zhang, J., Lung, R. W. M., TONG, J. H. M., Chan, A. W. H., Zhang, B., Wong, C. C., Wu, F., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0134-0 · Cited by 159
Neutrophils promote tumor resistance to radiation therapy
Wisdom, A. J., Hong, C. S., Lin, A. J., Xiang, Y., Cooper, D. E., Zhang, J., Xu, E. S., Kuo, H.-C., Mowery, Y. M., Carpenter, D. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901562116 · Cited by 167
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway
Ehmer, U., & Sage, J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0305 · Cited by 161
Chen, Y.-A., Lu, C.-Y., Cheng, T., Pan, S., Chen, H., & Chang, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00060 · Cited by 160
Crumbs3-Mediated Polarity Directs Airway Epithelial Cell Fate through the Hippo Pathway Effector Yap
Szymaniak, A. D., Mahoney, J. E., Cardoso, W. V., & Varelas, X. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.06.020 · Cited by 157
Huang, Y., Yang, C.-K., Wei, P., Huynh, T.-T., Whang‐Peng, J., Meng, T., Hsiao, M., Tzeng, Y., Wu, A. T. H., & Yen, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0421-3 · Cited by 155
Mechanoregulation and pathology of YAP/TAZ via Hippo and non‐Hippo mechanisms
Dobrokhotov, O., Samsonov, M., Sokabe, M., & Hirata, H. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0202-9 · Cited by 157
Metadata
- Authors
- Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., Zwang, Y., Roberts, T. M., Root, D. E., Jacks, T., & Hahn, W. C.
- Affiliations
- Broad Institute (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Jacks, Tyler
- Hahn, William C.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 158
- Issue
- 1
- Pages
- 171-184
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4110062
- OpenAlex
- W2064644124
- Cited by
- 744
- References
- 69
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 50 · 2023: 56 · 2022: 59 · 2021: 58 · 2020: 82 · 2019: 68 · 2018: 58 · 2017: 73 · 2016: 75 · 2015: 61 · 2014: 22
- FWCI
- 38.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (P30-CA14051, W81XWH)
- Howard Hughes Medical Institute
- American Association for Cancer Research
- Hope Funds for Cancer Research (HFCR-11-03-03)
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051)
- National Institutes of Health (W81XWH)
- National Cancer Institute (P50CA127003, K99CA169512, R01CA140545, CA14051, R00CA169512, P01CA050661, U01CA176058, P01CA154303, P30CA014051, P30-CA-14051)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- KRAS, YAP, oncogenic Ras, epithelial-mesenchymal transition, tumor cell survival, FOS, transcriptional coactivator, acquired drug resistance, colon cancer, lung cancer, cell transformation, transcriptional regulation
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Colonic Neoplasms, Humans, Lung Neoplasms, Phosphoproteins, Proto-Oncogene Proteins, Transcription Factors, Signal Transduction, Transcriptional Activation, Proto-Oncogene Proteins p21(ras), Drug Delivery Systems, ras Proteins, Cell Cycle Proteins, Drug Resistance, Neoplasm, HCT116 Cells, Adaptor Proteins, Signal Transducing, Mice, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
